Physician profile
David W Ray
NPI 1518030733
$3,137.37
in general payments reported to CMS, 2019-2025
30 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $524 · 2021: $553 · 2022: $440 · 2023: $212 · 2024: $444 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $822.18 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $304.58 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $296.07 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Merck Sharp & Dohme LLC | $250.11 | 2019-2022 | |
| Amgen INC. | $194.77 | 2019-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.15 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $120.76 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $119.91 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $104.51 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Exact Sciences Corporation | $79.94 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $67.82 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $66.94 | 2023-2024 | Voquezna |
| Pfizer INC. | $60.58 | 2019-2024 | |
| Amarin Pharma, INC. | $56.76 | 2019-2022 | |
| Abbvie INC. | $55.13 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $54.41 | 2019-2023 | |
| Dexcom, INC. | $34.89 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $33.52 | 2020-2021 | |
| Abbott Laboratories | $32.39 | 2022-2023 | Freestyle Libre 3 |
| Boston Scientific Corporation | $29.21 | 2025 | Watchman Access System |
| Glaxosmithkline, LLC. | $28.71 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.27 | 2022 | |
| Edwards Lifesciences Corporation | $22.06 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kowa Pharmaceuticals America, INC. | $16.99 | 2025 | Zoryve |
| Seqirus USA INC | $16.50 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Lucid Diagnostics INC. | $15.69 | 2022 | |
| Ibsa Pharma INC. | $12.39 | 2021 | |
| Genzyme Corporation | $12.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.24 | 2021 | |
| Daiichi Sankyo INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.